Table I.
Patient characteristics.
| Patient characteristics | N |
|---|---|
| Age, median (range) | 62 (24–84) |
| Sex, n (%) | |
| Male | 65 (51) |
| Female | 62 (49) |
| Stage, n (%) | |
| I | 20 (16) |
| II | 29 (23) |
| III | 34 (27) |
| IV | 44 (35) |
| Disease presentation, n (%) | |
| B | 39 (31) |
| X | 29 (23) |
| S | 26 (20) |
| Treatment cycles, median (range) | 8 (2–10)a |
| Consolidation radiotherapy | 57 (45) |
| Treatment response, n (%) | |
| CR | 103 (81) |
| PR | 8 (6) |
| SD | 1 (1) |
| PD | 10 (8) |
| IPI Group, n (%) | |
| Low | 37 (29) |
| Low intermediate | 36 (28) |
| High intermediate | 30 (24) |
| Highb | 24 (19) |
| Ki-67 expression, median % (range) | 80 (50–95) |
a
one patient received 10 cycles: 2 cycles of cyclophosphamide, vincristine, prednisone, and 8 cycles of rituximab and cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone following final staging
b
based on IPI score. B, constitutional symptoms; X, bulky disease; S, spleen involvement; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; Ki-67, proliferation marker protein Ki-67; IPI, International Prognostic Index.